Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin – EXENDA , a 24 week, prospective, randomized, placebo‐controlled pilot trial

Published 2021 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin – EXENDA , a 24 week, prospective, randomized, placebo‐controlled pilot trial
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-01-20
DOI
10.1111/dom.14319

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.